News for Merck & Co., Inc. (MRK)

Market Analysis by covering: Nasdaq 100, S&P 500, Dow Jones Industrial Average, Amgen Inc. Read 's Market Analysis on Investing.com

Merck (MRK) stock in focus as its lung disease drug Winrevair gains FDA priority review for a label update based on Phase 3 ZENITH trial results. Read more here.

Pelthos plans to launch ZELSUVMI™ for the treatment of Molluscum contagiosum infections in July 2025

Merck & Co., Inc.'s 4.09% dividend yield and robust pipeline signal strong growth potential. Click here to read an analysis of MRK stock now.

Merck remains a top Big Pharma name with strong leadership, rising sales, and high margins, despite regulatory fears and pressures. Learn why MRK stock is a buy.

Merck & Co., Inc. (NYSE:MRK) is one of the 12 stocks that will make you rich in 10 years. On June 23, the company shared encouraging results from its Phase 3 HYPERION trial. The study tested a drug called WINREVAIR (sotatercept-csrk) against a placebo, both combined with standard treatment, in adults recently diagnosed with pulmonary […]

Merck & Co., Inc. (NYSE:MRK) is one of the Best Stocks to Buy for Dividends. Merck & Co., Inc. (NYSE:MRK) is a leading pharmaceutical company, best known for its strong presence in oncology, particularly through Keytruda, the top-selling drug globally. Beyond cancer treatment, the company also produces medications for diabetes, as well as vaccines for […]

Merck's heavy reliance on Keytruda continues to grow, with the drug nearing 50% of total sales and limited growth from other products. Read why MRK is a Buy.

In this analysis, we explore the potential upside for Merck despite its short-term hurdles.

Merck (MRK) revealed that the Advisory Committee on Immunization Practices of the U.S. Centers for Disease Control and Prevention has voted to endorse Enflonsia

Merck & Co., Inc. (NYSE:MRK) is one of the 10 Best and Cheap Stocks to Buy Now. On June 18, Akash Tewari, an analyst from Jefferies, maintained the Buy rating on Merck & Co., Inc. (NYSE:MRK) with a price target of $138. The positive outlook is based on the stability of the company’s vaccine sales and […]

Merck (MRK) has reported promising results from its Phase 3 HYPERION trial, which evaluated the efficacy of WINREVAIR in adults recently diagnosed with pulmonar

Merck (MRK) shows promising results in its Winrevair trial for pulmonary arterial hypertension, signaling potential for reduced health risks. Analysts p

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced positive topline results from the Phase 3 HYPERION study evaluating WI

A heated debate over the U.S. healthcare system erupted on X, pitting billionaire entrepreneur Mark Cuban against Sen. Elizabeth Warren (D-Mass) over the root causes of soaring drug prices. What Happened: The clash, unfolding as of Friday, has ...

Abbott and MSD Pharmaceuticals partner to distribute oral anti-diabetic medicines in India, benefiting millions with Type 2 diabetes.

Key Takeaways: The CDC maintains the current dosing regimen for Merck's Gardasil HPV vaccine, supporting Merck's stance. Analysts project significant ups

Key Takeaways: Merck (MRK) is actively partnering with Chinese biotech firms, signaling growth in the sector. Analysts provide an average price target fo

The first patient has been dosed in the [url="]IDeate-Prostate01[/url] phase 3 trial evaluating the efficacy and safety of investigational ifinatamab deruxteca